CONSUMER PROTECTION IN GENOMIC TESTING SERVICES: LEGAL FRAMEWORK AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Genomic testing services involve analysing DNA to identify genetic variations, inherited disorders, disease susceptibility, ancestry, pharmacogenomic responses, and other biological characteristics. These services are provided by hospitals, diagnostic laboratories, genetic counsellors, biotechnology companies, and direct-to-consumer testing platforms.

Errors in genomic testing can result in misdiagnosis, unnecessary treatment, inappropriate reproductive decisions, psychological distress, privacy violations, and financial loss. Consumer protection law therefore plays an important role in ensuring accuracy, transparency, professional competence, and accountability.

In India, consumer protection for genomic testing is governed principally by the Consumer Protection Act, 2019, alongside applicable medical-device, clinical-establishment, genetic-testing, data-protection, and professional-regulation requirements. There is no single comprehensive statute exclusively regulating every form of genomic testing service.

2. STATUTORY FRAMEWORK IN INDIA

A. CONSUMER PROTECTION ACT, 2019

The Act protects consumers against deficient services, unfair trade practices, misleading advertisements, and other prohibited conduct. A person purchasing a genomic test for personal or medical purposes may qualify as a consumer, subject to the statutory definitions and applicable exceptions.

Section 2(11) defines deficiency in service, including shortcomings or inadequacies in the quality, nature, or manner of performance required by law or undertaken under a contract. Section 2(47) addresses unfair trade practices, including specified misleading representations.

A genomic testing provider may face liability where it supplies an incorrect report through negligent sample handling, inadequate quality control, avoidable analytical errors, or misleading representations about a test's accuracy. However, an unexpected result or an inherent scientific limitation does not automatically establish negligence.

B. PRE-CONCEPTION AND PRENATAL GENETIC TESTING

The Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994, regulates specified genetic counselling centres, genetic laboratories, and genetic clinics. It restricts prenatal diagnostic techniques to legally permitted purposes and prohibits sex selection and unlawful disclosure or use of fetal sex information.

The Supreme Court's interpretation of this legislation is particularly important for laboratories providing prenatal genetic testing. Compliance may require appropriate registration, prescribed records, qualified personnel, and adherence to statutory restrictions.

C. DIGITAL PERSONAL DATA PROTECTION

The Digital Personal Data Protection Act, 2023, may apply when genomic reports and associated records constitute digital personal data relating to identifiable individuals. Applicable obligations depend on the Act's commencement provisions, the nature of processing, and any relevant statutory exceptions.

The Information Technology Act, 2000, and applicable rules may also remain relevant to particular electronic records and data-security issues. Genomic laboratories should not assume that obtaining a sample automatically authorises unrestricted use, disclosure, or commercial exploitation of the resulting genetic information.

D. MEDICAL AND LABORATORY STANDARDS

Where applicable, the Medical Devices Rules, 2017, regulate relevant medical devices and in-vitro diagnostic products. Clinical laboratories should also assess applicable state clinical-establishment legislation, professional standards, recognised quality-management requirements, and laboratory accreditation conditions.

Accreditation under ISO 15189 may provide evidence of laboratory competence, but accreditation alone does not guarantee that every individual test result is accurate or eliminate legal liability.

3. ESSENTIAL CONSUMER RIGHTS AND PROVIDER OBLIGATIONS

A. ACCURATE TESTING AND REASONABLE PROFESSIONAL CARE

Providers must exercise reasonable care in sample collection, identification, storage, sequencing, interpretation, and reporting. They should implement validated procedures, contamination controls, proficiency testing, and documented quality assurance.

B. INFORMED CONSENT AND CLEAR DISCLOSURES

Before testing, consumers should receive understandable information about the test's purpose, limitations, possible incidental findings, and whether results require confirmatory testing. Genetic counselling may be particularly important for hereditary disorders and clinically significant findings.

C. TRANSPARENCY IN ADVERTISING

A provider should not claim that a genomic test definitively predicts cancer, intelligence, behaviour, or future disease where the evidence supports only a probability or limited association. Misleading claims about sensitivity, specificity, clinical validity, or diagnostic certainty may attract consumer-law scrutiny.

D. PRIVACY AND CONFIDENTIALITY

Providers should establish appropriate access controls and policies governing disclosure, retention, research use, and sharing of genetic data. Any consent or other legal basis must cover the relevant processing in accordance with applicable law.

E. COMPENSATION AND REDRESSAL

Depending on the facts, a consumer may seek a refund, compensation for proven loss, correction of deficient services, or other relief available under the Consumer Protection Act, 2019. The consumer must establish the relevant legal elements, including deficiency and causation where required.

4. IMPORTANT CASE LAWS

1. INDIAN MEDICAL ASSOCIATION V. V.P. SHANTHA (1995)

Citation: (1995) 6 SCC 651.

Authority: Direct authority on consumer protection for qualifying medical services; analogous to genomic testing services.

The Supreme Court held that qualifying medical services provided for consideration fall within the Consumer Protection Act, subject to the distinctions explained in the judgment. Services rendered entirely free of charge to every patient and certain employment-based services were treated differently.

Application: A paid genomic diagnostic service may fall within consumer jurisdiction if it satisfies the statutory requirements. The precise contractual and institutional arrangement must be examined.

2. SAILESH MUNJAL V. ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) (2004)

Forum: National Consumer Disputes Redressal Commission.

Authority: Direct authority involving prenatal DNA testing and consumer protection.

The dispute concerned prenatal testing for beta-thalassaemia, an erroneous diagnosis alleged by the complainants, and claims of negligence in DNA sample preparation and analysis. The Commission treated the complaint as maintainable but found insufficient evidence of negligence on the facts presented. It directed AIIMS to provide free treatment and medicines for the affected child.

Application: This is a particularly relevant Indian precedent demonstrating that genomic testing disputes require examination of sample-handling procedures, scientific limitations, expert evidence, and the actual cause of the error. An inaccurate result alone does not necessarily prove negligence.

3. G. VIJAYASHANKAR V. MADRAS MEDICAL MISSION (2021)

Forum: National Consumer Disputes Redressal Commission.

Authority: Directly relevant to genetic counselling and prenatal diagnostic services.

The dispute concerned alleged deficiencies in infertility treatment, genetic counselling, and advice about diagnostic testing in connection with the birth of a child with Down syndrome. The complaint was dismissed for insufficient proof of negligence.

Application: The case illustrates the importance of establishing what advice was required, what was actually communicated, and whether the provider departed from accepted professional standards. It does not establish that every failure to predict a genetic condition constitutes consumer-law liability.

4. UDAYAN V. IMAGING POINT (2022)

Forum: National Consumer Disputes Redressal Commission.

Authority: Analogous authority on diagnostic negligence.

The Commission considered allegations that congenital abnormalities had not been identified during prenatal ultrasound examinations and awarded compensation after finding negligence on the facts.

Application: Although ultrasound imaging is not genomic sequencing, the case illustrates how a diagnostic provider's failure to identify findings within the test's expected scope may result in consumer liability. Genomic laboratories can apply the same general principles only where the nature of the test and the evidence justify doing so.

5. V. KISHAN RAO V. NIKHIL SUPER SPECIALITY HOSPITAL (2010)

Citation: (2010) 5 SCC 513.

Authority: Direct authority on consumer medical-negligence procedure; analogous to genomic laboratory disputes.

The Supreme Court held that expert evidence is not mandatory in every medical-negligence case. Consumer fora must assess the facts and determine whether expert assistance is necessary.

Application: A genomic testing complaint involving an obvious sample-identification failure may be assessed differently from a dispute concerning complex variant interpretation. Technical expert evidence may be necessary where scientific issues cannot be resolved reliably without it.

6. FEDERATION OF OBSTETRICS AND GYNECOLOGICAL SOCIETIES OF INDIA V. UNION OF INDIA (2019)

Citation: (2019) 6 SCC 283.

Authority: Direct authority on compliance with prenatal diagnostic legislation; analogous to genomic testing regulation.

The Supreme Court emphasised the statutory requirements and documentation safeguards under the Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994. It stressed that prescribed records and procedural requirements are important to effective enforcement.

Application: Laboratories conducting covered prenatal genetic procedures must comply with applicable statutory registration, recordkeeping, and use restrictions. The decision reinforces that technical competence does not excuse non-compliance with mandatory legal safeguards.

5. PRACTICAL COMPLIANCE MEASURES

Genomic testing providers should maintain:

Documented sample identification, chain of custody, storage, and processing procedures.

Validated analytical methods, quality-control records, and documented limitations.

Clear reports distinguishing pathogenic findings, uncertain variants, and probabilistic risk estimates.

Appropriate consent, genetic counselling, and referral procedures where indicated.

Transparent pricing, turnaround times, limitations, and correction policies.

Confidentiality and data-security controls consistent with applicable law.

A complaints procedure, investigation of adverse incidents, and a documented corrective-action process.

Consumers should preserve invoices, consent forms, test reports, communications, and independent medical opinions. These records can assist in establishing the service supplied, the alleged deficiency, and any resulting harm.

6. CONCLUSION

Consumer protection in genomic testing requires a balance between scientific uncertainty and the duty to provide services with reasonable professional care. India's Consumer Protection Act, 2019, offers a potential remedy for negligent testing, misleading representations, and other actionable deficiencies, while prenatal genetic testing is subject to additional statutory restrictions.

The decisions in Sailesh Munjal, V. Kishan Rao, and Federation of Obstetrics and Gynecological Societies of India provide particularly useful guidance on DNA-testing disputes, professional negligence, and statutory compliance. Nevertheless, no cited decision establishes an automatic right to compensation whenever a genomic test produces an unexpected or incorrect result. Liability depends on the applicable legal duty, the evidence of deficiency or negligence, causation, and the loss proved. Clear disclosures, rigorous laboratory quality controls, appropriate consent, and effective complaint mechanisms remain central to responsible genomic testing services.